Most Clicked SNMMI SmartBrief Stories

1. Cardinal, Bayer partner on U.S. manufacturing facility

SNMMI SmartBrief | Dec 22, 2014

Cardinal Health will build a manufacturing site in Indiana under a 15-year deal with Bayer HealthCare. The facility will make Xofigo, or radium-223 dichloride, of which Cardinal is the lone U.S. distributor. Pharma Letter (U.K.) (subscription required), The (12/19) Business Standard (India) (12/22)

2. Total lesion glycolysis may shed light on NSCLC survival

SNMMI SmartBrief | Dec 23, 2014

Measuring total lesion glycolysis using FDG PET/CT after complete resection of lymph nodes in patients with non-small cell lung cancer could help predict outcomes, according to a study in the Journal of Nuclear Medicine. The study looked at 248 patients with type 1a or 1B cancer, finding five-year overall survival was at 93.7% for patients with low TLG and 78.3% for patients with high TLG as measured with imaging. (12/22)

3. NICE endorses Xofigo for certain men with prostate cancer

SNMMI SmartBrief | Dec 18, 2014

The National Institute for Health and Care Excellence has issued draft guidance recommending Bayer's Xofigo, or radium-223, for use in the National Health Service in Wales and England for docetaxel-treated patients with hormone-relapsed prostate cancer, symptomatic bone metastases and no apparent visceral metastases. The move is dependent upon discounts from Bayer. PharmaTimes (U.K.) (12/16)

4. 3D printing could be used to optimize radiopharmaceutical treatment

SNMMI SmartBrief | Dec 19, 2014

A team of researchers from the Institute of Cancer Research in London suggests that 3D-printed models of tumors could improve therapy by allowing doctors to observe the flow of radiopharmaceuticals. This technology could aid doctors in optimizing dosage of radiopharmaceutical agents. (12/17)

5. Mass General, Infraredx partner to advance CAD imaging

SNMMI SmartBrief | Dec 18, 2014

Infraredx has announced a multiyear collaboration with Massachusetts General Hospital and researcher Dr. Gary Tearney to develop new imaging technologies for the diagnosis of coronary artery disease. Tearney is known for pioneering research developing optical coherence tomography and Infraredx's near-infrared spectroscopy tools. (free registration) (12/16)

6. Report projects modest growth in global nuclear imaging market

SNMMI SmartBrief | Dec 19, 2014

The global market for nuclear imaging devices will expand from $1.83 billion in 2013 at a modest 3.3% compound annual growth rate to reach $2.2 billion in 2020, according to a GlobalData report. The U.S. market will generate about $1.15 billion throughout the forecast period and will see its global share fall from 69% in 2013 to 53% by 2020. Meanwhile, market share in the Asia-Pacific region will grow from 16% to 29%. (free registration) (12/17)

7. PET/CT before adjuvant therapy informs OSCC treatment, study finds

SNMMI SmartBrief | Dec 22, 2014

An additional PET/CT scan following surgery but before radiotherapy or chemoradiotherapy could improve disease management and predict survival among patients with oral squamous cell carcinoma, according to a 674-patient study in the Journal of Nuclear Medicine. Treatment plans were altered in 14% of patients based on the additional scans, the researchers report. (12/19)

8. Protein illuminates neural activity

SNMMI SmartBrief | Dec 19, 2014

A team led by Harvard University neuroscientist Adam Cohen has developed a way to convert neurons' electrical activity into fluorescent light, which might allow researchers to follow and measure brain activity in epilepsy, multiple sclerosis and other disorders. The researchers reverse-engineered a protein from Halorubrum sodomense, a single-celled organism found in the Dead Sea, to convert energy into light. Bloomberg (12/17)

9. FDA panel to study drug compounding

SNMMI SmartBrief | Dec 22, 2014

The FDA named members of a 14-member panel set up to advise the agency on scientific, technical and medical issues related to drug compounding. The panel includes physicians, pharmacists and regulatory experts. MedPage Today (free registration) (12/18)

10. Researchers trace possible mechanisms behind ALS motor neuron death

SNMMI SmartBrief | Dec 18, 2014

A study in the journal Neuron has found that aberrant repeat sequences in a gene linked to some cases of amyotrophic lateral sclerosis may be the cause of nerve damage by way of toxic RNA or protein products. According to researchers, the folded RNA generated by the mutated C9orf72 gene may disrupt cell function, while the protein created from that RNA tended to aggregate in the nucleolus, killing the neurons. Both pieces may be at work, the researchers argue. (12/17)

Sign up for SNMMI SmartBrief

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession. Learn more